Cambridge Healthtech Institute’s Inaugural

Bispecific Antibodies for Cancer Immunotherapy

Engineering Next-Generation Biotherapeutics in Immuno-Oncology

August 28-29, 2018

Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the next generation of immunotherapy. Cambridge Healthtech Institute’s Inaugural Bispecific Antibodies for Cancer Immunotherapy meeting will showcase preclinical, translational and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T-cell-redirecting bispecific biologics, overcoming T-cell exhaustion, as well as strategies to improve efficacy and reduce toxicity, and engineer the next generation of bi- and multi-specific biologics.


Preliminary Agenda

T CELL AND TUMOR REDIRECTING BISPECIFIC ANTIBODIES

T Cells Redirecting Bispecific Antibodies

Chien-Hsing Ken Chang, PhD, Vice President, Research and Development, Immunomedics

Selective Blockage of the Innate Immune Checkpoint Receptor CD47 on Mesothelin (MSLN) Positive Solid Tumor Cells via Dual Targeting Bispecific Antibodies

Stefano Majocchi, PhD, Research Scientist, Research Department, Novimmune SA

EpCAM-Targeted T Cell Engager

Volker Schellenberger, PhD, President & CEO, Amunix

PM-CD3: A Novel Highly Tumor-Specific T Cell Engaging Bispecific for the Treatment of Solid Tumors

Anika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH


ENGINEERING NOVEL CONSTRUCTS FOR DUAL ENGAGEMENT

KAHR Medical Dual Signaling Proteins (DSP) Platform: The Next Generation of Cancer Immunotherapy

Yaron Pereg, PhD, CEO, KAHR Medical, Ltd.

Optimization of a Bispecific Anti-CD3 Antibody-Small Molecule Conjugate for the Treatment of Ovarian Cancer

Harun Rashid, PhD, Principal Scientist, Molecular Technology, Ambrx

Development of MabPair Technology, a Novel Platform for Developing Bifunctional Antibody Products

Wei Yan, PhD, CEO, Research, Sound Biologics

ADAPTIR Bispecific Proteins: Stable, Manufacturable Therapeutics for Cancer Immunotherapy

David Bienvenue, PhD, Senior Director, Protein Sciences, Aptevo Therapeutics

Probody Therapeutics: Antibody Pro-Drugs Designed for Safer and More Effective Cancer Therapies

W. Michael Kavanaugh, MD, CSO, Head, Research and Non-Clinical Development, Cytomx Therapeutics


MULTI-SPECIFIC ANTIBODIES AND CONSTRUCTS

Using B-Body(TM) Bispecific Antibodies to Modulate Anti-Tumor Immune Responses

Bonnie Hammer, PhD, Vice President, Biologics Development, Invenra

A Novel Multi-Specific Antibody Targeting PD-L1-Overexpressing Cancers that Redirects and Stimulates Antigen-Committed CD8+ T Cells through Concomitant Engagement of a T Cell Costimulatory Receptor

David Urech, PhD, Co-CEO and CSO, R&D, Numab Therapeutics AG




For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com


For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

#IOSummit